Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856179 | 0.84 | KMT2A (0.73) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL2228231 | 0.83 | KMT2A (0.71) | KMT2AHPGDMEN1TSHRMAPK1 | |
| SCHEMBL20345004 | 0.82 | KMT2A (0.68) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL3455022 | 0.81 | HPGD (1.00) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL31680528 | 0.81 | TDP1 (0.77) | KMT2AHPGDMEN1TSHRMAPK1 | |
| SCHEMBL13534543 | 0.81 | KMT2A (0.68) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL20366867 | 0.81 | KMT2A (0.68) | KMT2AHPGDMEN1TSHRMAPK1 | |
| SCHEMBL15343524 | 0.80 | KMT2A (0.67) | KMT2AHPGDMEN1TSHRMAPK1 | |
| SCHEMBL19204050 | 0.80 | KMT2A (0.67) | KMT2AHPGDMEN1TSHRMAPK1 | |
| SCHEMBL20269157 | 0.80 | KMT2A (0.68) | KMT2AHPGDMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120184438-A1 | FORMULATIONS | SYNGENTA CROP PROTECTION, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184438-A1 | FORMULATIONS | SYNGENTA CROP PROTECTION, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011010082-A2 | FORMULATIONS | SYNGENTA LIMITED (GB) | 2011-01-27 | — | — | WO | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184438-A1 | FORMULATIONS | CBR3, H1-5, H1-0 | KMT2A 460/4885HPGD 3011/4885MEN1 244/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | KMT2A 1236/4885HPGD 1224/4885MEN1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.